Abstract:The ABCB1 transporter also known as P-glycoprotein (P-gp) is a transmembrane protein belonging to the ATP binding cassette super-family of transporters; it is a xenobiotic efflux pump that limits intracellular drug accumulation by pumping the compounds out of cells. P-gp contributes to a decrease of toxicity and possesses broad substrate specificity. It is involved in the failure of numerous anticancer and antiviral chemotherapies due to the multidrug resistance (MDR) phenomenon, where it removes the chemotherapeutics out of the targeted cells. Understanding the details of the ligand–P-gp interaction is therefore crucial for the development of drugs that might overcome the MRD phenomenon and for obtaining a more effective prediction of the toxicity of certain compounds. In this work, an in silico modeling was performed using homology modeling and molecular docking methods with the aim of better understanding the ligand–P-gp interactions. Based on different mouse P-gp structural templates from the PDB repository, a 3D model of the human P-gp (hP-gp) was constructed by means of protein homology modeling. The homology model was then used to perform molecular docking calculations on a set of thirteen compounds, including some well-known compounds that interact with P-gp as substrates, inhibitors, or both. The sum of ranking differences (SRD) was employed for the comparison of the different scoring functions used in the docking calculations. A consensus-ranking scheme was employed for the selection of the top-ranked pose for each docked ligand. The docking results showed that a high number of π interactions, mainly π–sigma, π–alkyl, and π–π type of interactions, together with the simultaneous presence of hydrogen bond interactions contribute to the stability of the ligand–protein complex in the binding site. It was also observed that some interacting residues in hP-gp are the same when compared to those observed in a co-crystallized ligand (PBDE-100) with mouse P-gp (PDB ID: 4XWK). Our in silico approach is consistent with available experimental results regarding P-gp efflux transport assay; therefore it could be useful in the prediction of the role of new compounds in systemic toxicity.

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Computationally accelerated identification of P-glycoprotein inhibitors

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Integration of Consensus‐Based Pharmacophore Mapping and Molecular Docking in Sequential Virtual Screening: Toward the Discovery of Novel PI3Kγ Inhibitors

Admet Evaluation in Drug Discovery. 13. Development of in Silico Prediction Models for P-Glycoprotein Substrates

Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays

Designing potent inhibitors against the multidrug resistance P-glycoprotein

Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein

Improved genome-scale multi-target virtual screening via a novel collaborative filtering approach to cold-start problem

Virtual Screening on Natural Products for Discovering Active Compounds and Target Information

Virtual screening of GPCRs: An in silico chemogenomics approach

Comparative Computational Screening of Natural-based Partial Agonists for PPARγ Receptor

Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors

Comprehensive Survey of Consensus Docking for High-Throughput Virtual Screening

Hybrid Virtual Screening Approach to Predict Novel Natural Compounds against HIV-1 CCR5

Discovery of Potent Inhibitors Against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(pyridin-2-yl)phenoxy)pyridine Analogue

Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning

Virtual Screening of a Chemically Diverse "Superscaffold" Library Enables Ligand Discovery for a Key GPCR Target

Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach

Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies